Oculis Holding AG (FRA:CR5) Research & Development: €60.68 Mil (TTM As of Mar. 2026)


FRA:CR5 Oculis Holding AG FRA:CR5
26 GF Score
Price €11.70
! 1 Warning Sign
View Full Analysis

What is Oculis Holding AG Research & Development?

Oculis Holding AG FRA:CR5 +1.74% 26 Research & Development is €60.68 Mil as of Mar. 2026. GuruFocus rates FRA:CR5 with a GF Score™ of 26/100. The stock has 1 warning sign investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Oculis Holding AG's Research & Development for the three months ended in Mar. 2026 was €15.43 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was €60.68 Mil.

Oculis Holding AG  (FRA:CR5) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Oculis Holding AG Research & Development Related Terms

Oculis Holding AG Research & Development Historical Data

* Premium members only.

The historical data trend for Oculis Holding AG's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oculis Holding AG Research & Development Chart

Oculis Holding AG Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial 9.19 22.52 31.01 55.79 61.18

Oculis Holding AG Quarterly Data
Dec20 Sep21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.46 15.90 15.11 14.24 15.43
FRA:CR5
26GF Score
Oculis Holding AG FRA:CR5
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oculis Holding AG Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €60.68 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €60.68 Mil mean?
Oculis Holding AG (FRA:CR5) has a Research & Development of €60.68 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Oculis Holding AG and its competitors.
Is Oculis Holding AG's Research & Development too high?
Oculis Holding AG's current Research & Development is €60.68 Mil. Overall, Oculis Holding AG has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Oculis Holding AG's Research & Development compare to NVCT and AURA?
Oculis Holding AG's Research & Development of €60.68 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Oculis Holding AG and its competitors. Oculis Holding AG's current Research & Development is €60.68 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oculis Holding AG stock overvalued right now?
Oculis Holding AG (FRA:CR5) has a current Research & Development of €60.68 Mil. The current Research & Development is €60.68 Mil. Oculis Holding AG's overall GF Score™ is 26/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Oculis Holding AG (FRA:CR5), the current Research & Development is €60.68 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Oculis Holding AG Business Description

Address Bahnhofstrasse 20, Zug, CHE, CH-6300
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.
26GF Score

Get the complete analysis for FRA:CR5

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€11.70
Price